Coya Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 | — |
| Operating income | -$22.6M | -$17.2M | -$7.9M | -$9.8M | -$4.9M |
| Operating expenses | $30.5M | $20.8M | $13.9M | $9.8M | $4.9M |
| Cash from operations | -$10.7M | -$10.3M | -$11.2M | -$7.2M | -$3.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M |
Shares outstanding 23.5M · Free float 84.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.